Sign In
Buy RGEN
$149.78
+2.72 (+1.85%)
At Close: Aug 04, 2026
Repligen Corporation (RGEN) Q3 2025 Earnings Call Transcript
05:01pm, Tuesday, 28'th Oct 2025
Repligen Corporation (NASDAQ:RGEN ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Jacob Johnson Olivier Loeillot - President, CEO & Director Jason Garland - CFO & Chief Compl
Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates
09:46am, Tuesday, 28'th Oct 2025
Repligen (RGEN) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.43 per share a year ago.
Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
07:30am, Tuesday, 28'th Oct 2025
WALTHAM, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its t
ALKS vs. RGEN: Which Stock Is the Better Value Option?
12:41pm, Tuesday, 21'st Oct 2025
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Alkermes (ALKS) or Repligen (RGEN). But which of these two stocks offers value investors a be
Earnings Preview: Repligen (RGEN) Q3 Earnings Expected to Decline
11:06am, Tuesday, 21'st Oct 2025
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
US Bancorp DE Sells 1,463 Shares of Repligen Corporation $RGEN
04:00am, Saturday, 18'th Oct 2025
US Bancorp DE cut its stake in Repligen Corporation (NASDAQ: RGEN) by 13.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The f
Repligen to Report Third Quarter 2025 Financial Results
07:30am, Wednesday, 15'th Oct 2025
Webcast and Conference Call to Be Held Tuesday, October 28, 2025, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, October 28, 2025, at 8:30 a.m. ET
Repligen Corporation (RGEN) Presents at Bank of America Global Healthcare Conference 2025 Transcript
11:37am, Thursday, 25'th Sep 2025
Repligen Corporation (NASDAQ:RGEN ) Bank of America Global Healthcare Conference 2025 September 25, 2025 6:35 AM EDT Company Participants Olivier Loeillot - President, CEO & Director Jason Garland - C
Repligen Corporation (RGEN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
10:32am, Thursday, 04'th Sep 2025
Repligen Corporation (NASDAQ:RGEN ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 8:00 AM EDT Company Participants Olivier Loeillot - President, CEO & Director Jason Garland - C
mRNA Biotechs - Long-Term Value Risks Abound
06:20am, Thursday, 28'th Aug 2025
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c
Repligen Corporation to Present at Upcoming September Conferences
07:30am, Friday, 22'nd Aug 2025
WALTHAM, Mass., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending
Repligen Corporation: Still Navigating Through The Covid Cliff
03:24pm, Thursday, 14'th Aug 2025
Repligen Corporation's Q2 results beat revenue expectations driven by strong revenue growth from consumables and biopharma sales. The company has diversified its product portfolio and customer base th
Repligen Stock Outlook: Risk Skewed To The Downside Through 2026
10:45am, Thursday, 31'st Jul 2025
Repligen RGEN has been in a steady downtrend for over 1400 days. Adhishthana principles suggest the weakness is likely to continue.
Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization
07:30am, Thursday, 31'st Jul 2025
WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have
Repligen Corporation (RGEN) Q2 2025 Earnings Call Transcript
05:31pm, Tuesday, 29'th Jul 2025
Repligen Corporation (NASDAQ:RGEN ) Q2 2025 Earnings Conference Call July 29, 2025 8:30 AM ET Company Participants Jacob Johnson - Corporate Participant Jason K. Garland - CFO & Chief Compliance Offic
